Brief: Moberg Pharma: Expert Evaluation Clarifies Phase 3 Results And Provides Strong Support For Mob-015

Moberg Pharma AB (publ)

22/01/2020 07:06

Jan 22 (Reuters) - Moberg Pharma AB (publ)  MBPH.ST :
    * EXPERT EVALUATION CLARIFIES PHASE 3 RESULTS AND PROVIDES STRONG SUPPORT FOR MOB-015
    * KEY CONCLUSIONS INCLUDE: I) MOB-015 DELIVERS A VERY HIGH MYCOLOGICAL CURE RATE THAT
COMPARES
FAVORABLY TO ORAL ANTIFUNGAL DRUGS WITH ADDED ADVANTAGE OF AN EARLIER ONSET OF ACTION;
    * KEY CONCLUSIONS INCLUDE: CONFIRMATION THAT PROPRIETARY VEHICLE TECHNOLOGY INCREASES
HYDRATION
AND PERMEABILITY OF NAIL PLATE ENABLING EFFICIENT TERBINAFINE DELIVERY, HOWEVER IT ALSO
CONFOUNDS ASSESSMENT OF CLINICAL CURE AND COMPLETE CURE
    * KEY CONCLUSIONS INCLUDE: LIKELY SOLUTION TO PROBLEM - A SHORTER DOSING REGIMEN WITH
POTENTIAL TO
DELIVER SUPERIOR COMPLETE CURE RATES

Source text for Eikon:  ID:nWkr9trgsR 
Further company coverage:  MBPH.ST 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))